Filing Details

Accession Number:
0000947871-21-000788
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-21 17:30:13
Reporting Period:
2021-07-19
Accepted Time:
2021-07-21 17:30:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1522860 Acutus Medical Inc. AFIB () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue
54Th Floor
New York NY 10022-4629
Yes No Yes No
1502240 Orbimed Capital Gp Iv Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
1767936 Orbimed Rof Ii Llc 601 Lexington Ave., 54Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-19 714,285 $14.00 4,872,025 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2021-07-19 357,143 $14.00 1,677,361 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 4,022 Indirect See Footnotes
Footnotes
  1. These shares of the Issuer's common stock were purchased in the Issuer's underwritten public offering.
  2. These shares of the Issuer's common stock are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP IV. OrbiMed Advisors and GP IV exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI IV.
  3. These shares of the Issuer's common stock are held of record by OrbiMed Royalty Opportunities II, LP ("ORO II"). OrbiMed ROF II LLC ("ROF II") is the general partner of ORO II, and OrbiMed Advisors is the managing member of ORO II. OrbiMed Advisors and ROF II exercise investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by ORO II.
  4. This report on Form 4 is jointly filed by GP IV, ROF II, and OrbiMed Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP IV have designated David Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons, or Bonita, is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
  5. Represents shares of the Issuer's common stock received by Bonita for service on the Issuer's board of directors. Pursuant to an agreement with OrbiMed Advisors and GP IV, Bonita is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed Advisors and GP IV, which will in turn ensure that such securities or economic benefits are provided to OPI IV.